UTILISATION DE VALERATE D'ESTRADIOL OU D'ESTRADIOL COMBINE A DU DIENOGEST POUR TRAITER PAR VOIE ORALE LA MENOMETRORRAGIE SOUS FORME UNITAIRE AVEC UN CONTRACEPTIF ORAL
The invention relates to the use of estradiol valerate or estradiol combinedwith 17a- cyanomethyl-17-~-hydroxyestra-4,9-diene-3on (dienogest) forproducing a multi-phase combination preparation for the oral therapy of thedysfunctional uterine bleeding in the form of oral contraceptives. Saidcombination of estradiol valerate or estradiol with dienogest comprises afirst phase consisting of 2 daily dose units of estradiol valerate at 3 mg orestradiol of less than 3mg, a second phase consisting of 2 groups of dailydose units, whereby the first group contains 5 daily dose units of acombination of 2 mg estradiol valerate or estradiol of less than 2mg and 2 mgof dienogest and the second group contains 17 daily dose units consisting of acombination of 2 mg of estradiol valerate or estradiol of less than 2mg and 3mg dienogest, a third phase consisting of 2 daily dose units having 1 mgestradiol valerate or estradiol of less than 2mg and an additional phaseconsisting of 2 daily dose units on a pharmaceutically harmless placebo. Allof the daily dose units of the multi-phase combination and thepharmaceutically harmless placebo correspond to 28 days. The duration ofapplication comprises at least one menstruation cycle and is dependent onindividual wishes of the woman with respect to contraception.
